|
Adult Liver Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Recent studies by us demonstrated that GCM is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity.
|
31840883 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Recent studies by us demonstrated that GCM is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity.
|
31840883 |
2019 |
|
Malignant neoplasm of liver
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Recent studies by us demonstrated that GCM is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity.
|
31840883 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The circRNA-miRNA-mRNA network was most involved in the MAPK, mTOR, AMPK, and WNT signaling pathways in Alzheimer's disease.
|
31834549 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of AMPK was performed to further examine the exact mechanism of LB100 in NAFLD.
|
31832001 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The signaling pathway activated by metformin (LKB1/AMPK/mTOR) is implicated in tumor suppression in ApcMin/+ mice via metformin-induced reduction in polyp burden, increased ratio of pAMPK/AMPK, decreased pmTOR/mTOR ratio, and decreased pS6Ser235/S6Ser235 ratio in polyps.
|
31818851 |
2020 |
|
polyps
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The signaling pathway activated by metformin (LKB1/AMPK/mTOR) is implicated in tumor suppression in ApcMin/+ mice via metformin-induced reduction in polyp burden, increased ratio of pAMPK/AMPK, decreased pmTOR/mTOR ratio, and decreased pS6Ser235/S6Ser235 ratio in polyps.
|
31818851 |
2020 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The Potential Synergistic Modulation of AMPK by <i>Lippia citriodora</i> Compounds as a Target in Metabolic Disorders.
|
31817196 |
2019 |
|
Polycystic Kidney, Autosomal Dominant
|
0.020 |
Biomarker
|
disease |
BEFREE |
One alternative possibility is that metabolic and mitochondrial dysfunctions in ADPKD are secondary to the de-regulation of proliferation, driven by the multiple signaling pathways identified in the disease, which include mTORC1 and AMPK among the most relevant.
|
31816397 |
2019 |
|
Degenerative polyarthritis
|
0.060 |
Biomarker
|
disease |
BEFREE |
This study provided evidence that active VD might activate chondrocyte autophagy to reduce OA inflammation via activating the AMPK/mTOR signaling pathway.
|
31815524 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, these results suggest that combining restrictive glucose uptake and targeting HSF1/AMPKα2 is an attractive strategy to prevent chemoresistance to OXA in HCC patients.
|
31815039 |
2019 |
|
Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the efficacy of combination treatment with TRAIL-secreting human mesenchymal stem cells (MSC-TRAIL) and compound C, an AMP-activated protein kinase (AMPK inhibitor), on glioblastoma.
|
31810928 |
2019 |
|
Glioblastoma Multiforme
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the efficacy of combination treatment with TRAIL-secreting human mesenchymal stem cells (MSC-TRAIL) and compound C, an AMP-activated protein kinase (AMPK inhibitor), on glioblastoma.
|
31810928 |
2019 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the efficacy of combination treatment with TRAIL-secreting human mesenchymal stem cells (MSC-TRAIL) and compound C, an AMP-activated protein kinase (AMPK inhibitor), on glioblastoma.
|
31810928 |
2019 |
|
Childhood Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the efficacy of combination treatment with TRAIL-secreting human mesenchymal stem cells (MSC-TRAIL) and compound C, an AMP-activated protein kinase (AMPK inhibitor), on glioblastoma.
|
31810928 |
2019 |
|
Alzheimer's Disease
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggest that diet control to achieve euglycaemia in an insulin-deficient DM condition may be harmful because of the greater possibility of AD development through increased tau phosphorylation by AMPK activation in the hippocampus.
|
31799531 |
2020 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Since AMPK is a direct regulator of tau phosphorylation, we hypothesized that strict diet control to achieve euglycaemia affects tau protein phosphorylation through increased AMPK activity in the hippocampus of DM rats.
|
31799531 |
2020 |
|
Adult Liver Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Current data showed that there were AMPK-ERK/CARM1 autophagic signaling pathways during the formation of liver cancer.
|
31799198 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Current data showed that there were AMPK-ERK/CARM1 autophagic signaling pathways during the formation of liver cancer.
|
31799198 |
2019 |
|
Malignant neoplasm of liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
Current data showed that there were AMPK-ERK/CARM1 autophagic signaling pathways during the formation of liver cancer.
|
31799198 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our discovery revealed that metformin, via increasing the expression of microRNA-7 mediated by AMPK, regulates the AKT/mTOR, MAPK/Erk, and NF-κB signaling pathways, thereby suppressing A549 cell growth, migration, and invasion.
|
31789625 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AMPK is generally a tumor suppressor.However, once cancer arises, AMPK becomes a tumor promoter instead, driving cancer development.
|
31787232 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AMPK is generally a tumor suppressor.However, once cancer arises, AMPK becomes a tumor promoter instead, driving cancer development.
|
31787232 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
AMPK is generally a tumor suppressor.However, once cancer arises, AMPK becomes a tumor promoter instead, driving cancer development.
|
31787232 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results establish that metformin AMPK-independently protects against palmitate-induced hepatic cell death by moderate inhibition of the mitochondrial respiratory chain, recovering mitochondrial function, decreasing cellular ROS production, and inducing SOD2 expression, indicating that metformin may have beneficial actions beyond its glucose-lowering effect and also suggests that mitochondrial complex І may be a therapeutic target in NAFLD.
|
31786336 |
2020 |